Allogeneic stem-cell transplantation provides excellent results in advanced stage chronic myeloid leukemia with major cytogenetic response to pre-transplant imatinib therapy

References

• Druker B J, Sawyers C L, Kantarjian H, Resta D J, Reese S F, Ford J M, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001; 344: 1038–1042
   PubMed Web of Science ®Google Scholar
• Druker B J, Talpaz M, Resta D J, Peng B, Buchdunger E, Ford J M, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344: 1031–1037
   PubMed Web of Science ®Google Scholar
• O'Brien S G, Guilhot F, Larson R A, Gathmann I, Baccarani M, Cervantes F, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348: 994–1004
   PubMed Web of Science ®Google Scholar
• Sawyers C L, Hochhaus A, Feldman E, Goldman J M, Miller C B, Ottmann O G, et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 2002; 99: 3530–3539
   PubMed Web of Science ®Google Scholar
• Talpaz M, Silver R T, Druker B J, Goldman J M, Gambacorti-Passerini C, Guilhot F, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 2002; 99: 1928–1937
   PubMed Web of Science ®Google Scholar
• Hehlmann R, Hochhaus A, Kolb H J, Hasford J, Gratwohl A, Heimpel H, et al. Interferon-α before allogeneic bone marrow transplantation in chronic myelogenous leukemia does not affect outcome adversely, provided it is discontinued at least 90 days before the procedure. Blood 1999; 94: 3668–3677
   PubMed Web of Science ®Google Scholar
• Gratwohl A, Hermans J, Goldman J M, Arcese W, Carreras E, Devergie A, , for Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation, et al. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Lancet 1998; 352: 1087–1092
   PubMed Web of Science ®Google Scholar
• Bornhauser M, Kroger N, Schwerdtfeger R, Schafer-Eckart K, Sayer H G, Scheid C, , for the Cooperative German Transplant Study Group, et al. Allogeneic haematopoietic cell transplantation for chronic myelogenous leukaemia in the era of imatinib: a retrospective multicentre study. Eur J Haematol 2006; 76: 9–17
   PubMed Web of Science ®Google Scholar
• Visani G, Rosti G, Bandini G, Tosi P, Isidori A, Malagola M, et al. Second chronic phase before transplantation is crucial for improving survival of blastic phase chronic myeloid leukaemia. Br J Haematol 2000; 109: 722–728
   PubMed Web of Science ®Google Scholar
• Schoch C, Schnittger S, Bursch S, Gerstner D, Hochhaus A, Berger U, et al. Comparison of chromosome banding analysis, interphase- and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: a study on 350 cases. Leukemia 2002; 16: 53–59
   PubMed Web of Science ®Google Scholar
• Weisser M, Schleuning M, Ledderose G, Rolf B, Schnittger S, Schoch C, et al. Reduced-intensity conditioning using TBI (8 Gy), fludarabine, cyclophosphamide and ATG in elderly CML patients provides excellent results especially when performed in the early course of the disease. Bone Marrow Transplant 2004; 34: 1083–1088
   PubMed Web of Science ®Google Scholar
• Schmid C, Schleuning M, Ledderose G, Tischer J, Kolb H J. Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol 2005; 23: 5675–5687
   PubMed Web of Science ®Google Scholar
• Thomas E D, Storb R, Clift R A, Fefer A, Johnson L, Neiman P E, et al. Bone-marrow transplantation (second of two parts). N Engl J Med 1975; 292: 895–902
   PubMed Web of Science ®Google Scholar
• Deininger M, Schleuning M, Greinix H, Sayer H G, Fischer T, Martinez J, , for the European Blood and Marrow Transplantation Group, et al. The effect of prior exposure to imatinib on transplant-related mortality. Haematologica 2006; 91: 452–459
   PubMed Web of Science ®Google Scholar
• McGlave P B, Shu X O, Wen W, Anasetti C, Nademanee A, Champlin R, et al. Unrelated donor marrow transplantation for chronic myelogenous leukaemia: 9 years' experience of the National Marrow Donor Program. Blood 2000; 95: 2219–2225
   PubMed Web of Science ®Google Scholar
• Gale R P, Hehlmann R, Zhang M J, Hasford J, Goldman J M, Heimpel H, , for the German CML Study Group, et al. Survival with bone marrow transplantation versus hydroxyurea or interferon for chronic myelogenous leukemia. Blood 1998; 91: 1810–1819
   PubMed Web of Science ®Google Scholar
• Schaich M, Schakel K, Illmer T, Ehninger G, Bornhauser M. Severe epidermal necrolysis after treatment with imatinib and consecutive allogeneic hematopoietic stem cell transplantation. Ann Hematol 2003; 82: 303–304
   PubMed Web of Science ®Google Scholar
• Kim D W, Chung Y J, Lee S, Kim Y J, Chung N G, Kim J A, et al. Pretransplant imatinib can improve the outcome of nonmyeloablative stem cell transplantation without increasing the morbidity in Philadelphia chromosome-positive chronic myeloid leukemia. Leukemia 2004; 18: 1907–1909
   PubMed Web of Science ®Google Scholar
• Koch M, Lang P, Bader P, Kreyenberg H, Schumm M, Scheel-Walter H, et al. Successful unrelated allogeneic stem cell transplantation after treatment of lymphoid blast crisis CML with imatinib and imatinib-containing conditioning regimen in a 16-year-old male. Bone Marrow Transplant 2003; 32: 541–542
   PubMed Web of Science ®Google Scholar
• Staber P B, Brezinschek R, Linkesch W, Sill H, Neumeister P. Durable molecular response to imatinib mesylate following nonmyeloablative allogeneic stem-cell transplantation for persisting myeloid blast crisis in chronic myeloid leukemia. Haematologica 2003; 88: ECR29
   PubMedGoogle Scholar
• Koh L P, Hwang W Y, Chuah C T, Linn Y C, Goh Y T, Tan C H, et al. Imatinib mesylate (STI-571) given concurrently with nonmyeloablative stem cell transplantation did not compromise engraftment and resulted in cytogenetic remission in a patient with chronic myeloid leukemia in blast crisis. Bone Marrow Transplant 2003; 31: 305–308
   PubMed Web of Science ®Google Scholar
• Zander A R, Zabelina T, Renges H, Schider H, Kratochwille A, Fehse N, et al. Pretreatment with Glivec increases transplant related mortality after allogeneic transplant. Blood 2003; 102, (abstract 468a)
   PubMed Web of Science ®Google Scholar
• Shimoni A, Kroger N, Zander A R, Rowe J M, Hardan I, Avigdor A, et al. Imatinib mesylate (STI571) in preparation for allogeneic hematopoietic stem cell transplantation and donor lymphocyte infusions in patients with Philadelphia-positive acute leukemias. Leukemia 2003; 17: 290–297
   PubMed Web of Science ®Google Scholar
• Wassmann B, Pfeifer H, Scheuring U, Klein S A, Gokbuget N, Binckebanck A, et al. Therapy with imatinib mesylate (Glivec) preceding allogeneic stem cell transplantation (SCT) in relapsed or refractory Philadelphia-positive acute lymphoblastic leukemia (Ph + ALL). Leukemia 2002; 16: 2358–2365
   PubMed Web of Science ®Google Scholar